E
Telomir Pharmaceuticals, Inc. TELO
$5.03 $0.091.82%
Recommendation
Sell
Prev Close
$5.03
Volume
12
Avg Vol (90D)
168,941
Market Cap
$149.71M
Dividend & Yield
--
52-Week Range
$3.11 - $9.39
P/E (TTM)
--
EPS (TTM)
-$0.5741
My Lists My Alerts
Rating
Reward
E
Very Weak
Risk
E+
Very Weak
Rating Factors
Growth Index
Weak
Efficiency Index
Very Weak
Solvency Index
Good
Total Return Index
Very Weak
Volatility Index
Weak
Dividend Index
--
Headlines
Analysts Anticipate 30% Gains Ahead For The Holdings of VTWV
3/11/2025 - ETF Channel
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 34.4% in February
3/4/2025 - MarketBeat
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the ...
2/26/2025 - GuruFocus
Telomir Pharmaceuticals announces new Telomir-1 preclinical findings
2/26/2025 - The Fly
Telomir Pharmaceuticals Announces Breakthrough: Telomir-1 Reverses Calcium Dysregulation, the Hidden Driver of Aging and Disease, in Multiple Human Cell Lines
2/26/2025 - Accesswire
Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines
2/25/2025 - Seeking Alpha - Healthcare
Telomir Pharmaceuticals announces Telomir-1 reverses calcium dysregulation in multiple human cell lines
2/25/2025 - SeekingAlpha.com: All News
Rodman & Renshaw Begins Coverage on Telomir Pharmaceuticals (NASDAQ:TELO)
2/22/2025 - MarketBeat
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a ...
2/21/2025 - GuruFocus
Telomir Pharmaceuticals Achieves Breakthrough in Silver Ion Stabilization, Unlocking a Multi-Billion-Dollar Medical Market
2/21/2025 - Accesswire
Telomir Pharmaceuticals initiated with bullish view at Rodman & Renshaw, here's why
2/20/2025 - The Fly
Telomir Pharmaceuticals achieves breakthrough in silver ion stabilization
2/20/2025 - Seeking Alpha - Healthcare
Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration
2/20/2025 - Benzinga
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal ...
2/18/2025 - GuruFocus
Telomir Pharmaceuticals announces results from preclinical studies of Telomir-1
2/18/2025 - The Fly
Telomir Pharmaceuticals Announces Significant Reduction of Oxidative Stress in Human Retinal Cell Lines, Advancing Potential Treatment for Age-Related Macular Degeneration (AMD)
2/18/2025 - Accesswire
Telomir Pharmaceuticals files $150M mixed securities shelf
2/14/2025 - The Fly
Telomir Pharmaceuticals (NASDAQ:TELO) Releases Earnings Results, Misses Estimates By $0.05 EPS
2/5/2025 - MarketBeat
Telomir Pharmaceuticals announces results from preclinical studies of Telomir-1
1/28/2025 - The Fly
Telomir Pharmaceuticals Announces Breakthrough Results With Telomir-1 Fully Reversing Oxidative Stress in Human Cell Lines and Exploring Potential as a Treatment for Avian Influenza (Bird Flu) and Other Viruses
1/28/2025 - Accesswire
Telomir Pharmaceuticals, Inc. (NASDAQ:TELO) Short Interest Up 58.9% in December
1/17/2025 - MarketBeat
Telomir Pharmaceuticals, Inc.'s (NASDAQ:TELO) market cap surged US$16m last week, retail investors who have a lot riding on the company were rewarded
1/16/2025 - Simply Wall St
Geode Capital Management LLC Raises Stake in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)
1/9/2025 - Ticker Report
Geode Capital Management LLC Grows Stock Holdings in Telomir Pharmaceuticals, Inc. (NASDAQ:TELO)
1/9/2025 - MarketBeat
Telomir Pharmaceuticals Confirms Lifespan Restoration and Normalization of Accelerated Aging in ...
1/7/2025 - GuruFocus
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
--
EBIT (TTM)
-$12.30M
Net Income (TTM)
-$16.59M
Balance Sheet
Total Assets (Q)
$1.32M
Total Debt (Q)
$93.40K
Total Liabilities (Q)
$681.00K
Book Value Per Share (Q)
$0.0216
Cash Flow
Cash from Operations (TTM)
-$5.07M
Cash from Investing (TTM)
--
Cash from Financing (TTM)
$6.34M
Net Change in Cash (TTM)
$1.26M
Filings
Filing Date
Tuesday, February 4, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of Mar 24 and 28 (est)
Price History
Loading...
Beta
--
7-Day Total Return
21.79%
30-Day Total Return
11.28%
60-Day Total Return
-3.27%
90-Day Total Return
23.89%
Year to Date Total Return
23.59%
1-Year Total Return
-22.73%
2-Year Total Return
--
3-Year Total Return
--
5-Year Total Return
--
52-week Low
Aug 02, 2024 - $3.11
52-week High
Apr 16, 2024 - $9.39
Valuation
Market Cap
$149.71M - Micro Cap
Enterprise Value
$148.53M
Price/Sales (TTM)
--
Price/Book (Q)
232.87
Dividends and Shares
Shares Outstanding
29.66M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
telomirpharma.com
Phone Number
786 396 6723
Address
100 SE 2nd Street
Miami, FL 33131
Country
United States
Year Founded
2021
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Telomir Pharmaceuticals, Inc., a pre-clinical stage biopharmaceutical company, focuses on developing pharmaceutical products for reversal of oxidative stress, cellular protection, and regulatory... more
NASDAQ 03/13/2025 4:00PM Eastern Quotes delayed
Weiss Ratings